- Acquisition of Staccato® One Breath Expertise®, a proprietary platform know-how with broad therapeutic potential
- Synergistic and complementary to Lee’s Pharm’s present merchandise pipeline, and
- Acquisition of rights as licensor and producer of Staccato® alprazolam beneath a worldwide partnership with UCB
HONG KONG, Dec. 9, 2025 /PRNewswire/ — Nova Pneuma Inc. (“NPI”), the Delaware integrated and wholly owned subsidiary of Lee’s Pharmaceutical Holdings Restricted (0950.HK) (“Lee’s Pharm” or the “Firm”), introduced in the present day the belongings acquisition from Alexza Prescription drugs, Inc. (“Alexza”). The transaction grants Lee’s Pharm and NPI, the complete possession of the Staccato® One Breath Expertise® (“Staccato® OBT®”) platform and belongings in relation to Staccato® OBT®, together with mental property, know-how, emblems, product pipeline, tools, merchandise and entry to GMP facility, and Alexza’s proper as licensor and producer of Staccato® alprazolam. This strategic transfer strengthens Lee’s Pharm’s aerosolized inhalation drug supply capabilities, expands the Firm’s inhalation product pipeline, and aligns with the Firm’s world enlargement technique.
The transaction stays topic to sure closing situations and is predicted to shut by the top of 2025.
Proprietary And Properly-Validated Staccato® One Breath Expertise®
The acquisition of the Staccato® OBT® platform represents a serious step ahead for the Firm, granting full possession of this know-how platform which is a well-validated and confirmed platform supported by accepted product, Adasuve®, and several other Staccato® based mostly late-stage growth applications. This strategic transfer strengthens the Firm’s drug supply capabilities and positions it to drive future innovation in inhalation therapeutics.
Synergistic and Complementary to Lee’s Pharm’s Current Merchandise Pipeline
The transaction additionally delivers vital synergies with the Firm’s present pipeline. The Firm has been advancing its medical growth of Staccato® based mostly drugs for cancer-related breakthrough ache and began commercializing Adasuve® for acute agitation in grownup schizophrenia or bipolar I dysfunction throughout Larger China. Upon completion of the acquisition, all licensing fee obligations payable thereafter by Lee’s Pharm to Alexza for the event and commercialization of Staccato® based mostly drugs and Adasuve®, can be eradicated, delivering quick price financial savings and enhancing total deal economics.
As well as, two promising CNS pipeline belongings focusing on Parkinson’s illness and Cyclic Vomiting Syndrome (CVS), each at Section 2 medical stage, can be built-in into the Firm’s portfolio, unlocking new business alternatives.
Acquisition of Rights as Licensor and Producer of Staccato® alprazolam Underneath a World Partnership With UCB
Complementing these advantages, the Firm acquires Alexza’s rights and obligations beneath the present worldwide licensing and manufacturing provide settlement with UCB, a biopharmaceutical with sturdy presence in epilepsy remedy. Underneath this settlement, UCB holds and can hold world growth and commercialization rights for Staccato® alprazolam, which is at present in Section 3 medical trial (CinicalTrial.gov ID: NCT05077904), reinforcing the medical maturity and business potential of the Staccato® OBT® platform. UCB acquired Engaged Therapeutics, Inc. for Staccato® alprazolam in June 2020 and entered into an up to date license and associated business provide settlement with Alexza.[1]
Topic to reaching specified growth, regulatory, and gross sales milestones, Lee’s Pharm along with NPI might obtain milestone funds totalling as much as US$60.5 million, together with tiered royalties on world web gross sales of Staccato® alprazolam, along with manufacturing income from worldwide provide of Staccato® alprazolam.
Notice: [1] Supply of reference: https://www.ucb.com/newsroom/press-releases
“Buying the Staccato® OBT® platform is a transformative step for Lee’s Pharm, reinforcing our dedication to innovation in inhalation therapeutics focusing on CNS and neurodegenerative issues, and increasing our world footprint.” stated Dr. Benjamin Li, Founder and Director of Lee’s Pharmaceutical Holdings Restricted. “This transaction not solely strengthens our pipeline and inhalation R&D capabilities but in addition creates new income streams via the strategic partnerships with UCB.”
” We’re delighted to accomplice with UCB because it commits and advances options to handle important unmet wants in epileptic seizure remedy. This transaction not solely delivers near-term monetary advantages but in addition positions us for sustained progress in high-value therapeutic areas, marking a major milestone within the Firm’s world enlargement technique.” stated Ms. Wanee Lee, Managing Director of Lee’s Pharmaceutical Holdings Restricted.
“Underneath the brand new management, our staff is energized to proceed collaborating intently with UCB and to make sure the dependable manufacture of significant remedy for sufferers with vital unmet wants. We’re equally excited in regards to the alternative to carry further Staccato® based mostly medicines to sufferers all over the world, strengthening our shared dedication to enhancing lives via revolutionary science.” stated Dr. Wolfgang Schmidt, SVP Manufacturing and Operations at NPI.
About Lee’s Pharmaceutical Holdings Restricted
The Firm is a research-driven and market-oriented biopharmaceutical firm with greater than over 30 years of operation’ expertise within the pharmaceutical trade in China. The Firm is totally built-in with stable infrastructures in drug growth, medical growth, regulatory, manufacturing, gross sales and advertising based mostly in Mainland China with world views. The Firm has established in depth partnerships with round 30 worldwide firms and at present markets over 25 proprietary, generic and licensed-in pharmaceutical merchandise in Mainland China, Hong Kong, Macau and Taiwan. The Firm focuses on a number of key illness therapeutic areas equivalent to cardiovascular well being, girl’s well being, paediatrics, uncommon ailments, oncology, dermatology and obstetrics.
Extra info out there at www.leespharm.com.
About Staccato® One Breath Expertise®
The Staccato® One Breath Expertise® is a novel and extremely differentiated drug supply know-how that delivers excipient free drug as quick as intra-venous injection, however non-invasively, leading to fast onset of therapeutic impact. It’s best positioned for remedy of acute situations that require fast aid. The power of the know-how with the mix of various molecules to provide response to unmet medical wants in an revolutionary method has been properly confirmed in giant variety of medical research with completely different compounds and throughout variety of indications.
The proprietary know-how is properly protected by giant numbers of patents throughout completely different therapeutic areas.
Extra info out there at https://staccatoobt.com.
View authentic content material to obtain multimedia:https://www.prnewswire.com/news-releases/lees-pharmaceutical-holdings-limited-acquires-staccato-one-breath-technology-platform-and-assets-driving-pipeline-expansion-and-advancing-global-partnership-with-ucb-through-acquired-rights-302636404.html
SOURCE Lee’s Pharmaceutical Holdings Restricted
Leave a Reply